Meeting
2018 ASCO Annual Meeting
A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous non-small cell lung cancer (sqNSCLC) previously treated with platinum-based chemotherapy.
Authors
Giorgio V. Scagliotti
Department of Oncology - University of Torino, Turin, Italy
Giorgio V. Scagliotti , Igor Bondarenko , Tudor-Eliade Ciuleanu , Maciej Bryl , Andrea Fülöp , David Vicente , Helge Bischoff , Karla Hurt , Yi Lu , Shawn Estrem , Sameera R. Wijayawardana , Alan Chiang , Ramaswamy Govindan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02450539
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9059)
DOI
10.1200/JCO.2018.36.15_suppl.9059
Abstract #
9059
Poster Bd #
382
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous cell lung cancer (SqCLC) previously treated with platinum-based chemotherapy.
First Author: Giorgio V. Scagliotti
Poster
2022 ASCO Annual Meeting
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
First Author: Yuangyuan Zhao
Poster
2018 ASCO Annual Meeting
A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.
First Author: Jonathan Wade Goldman
Poster
2017 ASCO Annual Meeting
A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C.
First Author: Martin J. Edelman